LeewayTech

Your digital analyst! AI-powered automatic stock analyses for the global stock universe. Privacy policy and imprint at

[Leeway @PWPLeewayEN]

🏦 𝐔𝐏𝐃𝐀𝐓𝐄 | Powered by Leeway AI
$MU | 𝐒𝐞𝐥𝐥𝐢𝐧𝐠 𝐎𝐮𝐭 𝐓𝐡𝐞 𝐀𝐈 𝐒𝐮𝐩𝐞𝐫𝐜𝐲𝐜𝐥𝐞

𝐓𝐋;𝐃𝐑 Revenue up 4x year-over-year, entire 2026 HBM output already sold and contracted. Micron locked in ~$𝟐𝟐𝐁 in long-term deals and pivoted the business toward hyperscalers. The capex bill is the price of admission. The catalyst here is demand visibility, not just growth. Micron's fiscal Q3 revenue came in more than 𝐟𝐨𝐮𝐫 𝐭𝐢𝐦𝐞𝐬 the prior-year period, but the number that matters more is the backlog.

📈 Sixteen long-term contracts worth roughly $𝟐𝟐 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 now underpin future revenue, and the company's 𝐞𝐧𝐭𝐢𝐫𝐞 𝟐𝟎𝟐𝟔 𝐇𝐁𝐌 𝐩𝐫𝐨𝐝𝐮𝐜𝐭𝐢𝐨𝐧 𝐢𝐬 𝐬𝐨𝐥𝐝 𝐨𝐮𝐭 under fixed price and volume terms. In a business historically punished for its cyclicality, that is an unusual degree of forward certainty. ℹ️ Supply, not demand, is the binding constraint. Management expects HBM tightness to persist through 2026 and beyond, and HBM4 is shipping 𝐚𝐡𝐞𝐚𝐝 𝐨𝐟 𝐬𝐜𝐡𝐞𝐝𝐮𝐥𝐞 — a signal that Micron is keeping pace at the leading edge rather than trailing it.

✅ The buildout is already in motion:
first concrete poured at the Clay, New York facility, and India's first assembly-and-test plant is open. Behind these sits a planned $𝟐𝟓𝟎 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 US investment program through 2035. The strategic shift is quieter but real. Micron is winding down its consumer-facing Crucial business and steering toward enterprise, cloud and AI infrastructure buyers. That moves the revenue base toward fewer, larger, stickier customers — higher quality, more concentration.

⚠️ The cost of all this is cash. Net capex of roughly $𝟐𝟕 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 for 2026 materially constrains free cash flow despite record profitability, which caps near-term shareholder returns. Record earnings and thin free cash flow can coexist here, and for now they do. 𝐊𝐞𝐲 𝐃𝐫𝐢𝐯𝐞𝐫𝐬:

• 𝐂𝐨𝐧𝐭𝐫𝐚𝐜𝐭𝐞𝐝 𝐁𝐚𝐜𝐤𝐥𝐨𝐠: ~$𝟐𝟐𝐁 across 16 long-term deals; 2026 HBM fully sold out on fixed price/volume terms.
• 𝐂𝐚𝐩𝐚𝐜𝐢𝐭𝐲 𝐁𝐮𝐢𝐥𝐝𝐨𝐮𝐭: Up to $𝟐𝟓𝟎𝐁 in US investment through 2035; new fabs in New York and India's first ATMP plant.
• 𝐂𝐮𝐬𝐭𝐨𝐦𝐞𝐫 𝐌𝐢𝐱 𝐒𝐡𝐢𝐟𝐭: Exiting consumer Crucial line, concentrating on hyperscalers and AI infrastructure.

🧠 𝐋𝐞𝐞𝐰𝐚𝐲 𝐕𝐞𝐫𝐝𝐢𝐜𝐭:
The demand story is as clear as it gets for a memory maker. Watch free cash flow against the ~$𝟐𝟕𝐁 capex load — that gap, not the order book, will decide when capital returns to shareholders. Also worth tracking: how durable HBM pricing stays once supply eventually catches up.

📉 Full Data & Interactive Charts: https://leeway. tech/en/aktienanalyse/Micron%20Technology

Disclaimer: This is not financial advice. Based on Leeway AI model outputs.

MU SPX500 EUSTX50

[Trader Z @TraderZ]

How did @finviz_com get suspended? That sucks...

[LeewayTech @quant1212]

@FedProm Similar problem here. Rust issues, 3k+ to repair, 5k value. 31 year old Benz. Will keep it still I think because I hate beeping modern cars and because that model has the best motor ever build by Mercedes. But moneyview: not the best decision.

[Leeway @PWPLeewayEN]

Current #Russell2000 Flop #Stocks!

FuelCell Energy Inc: -11.83% (22.89$)
Jack in the Box Inc.: -11% (13.96$)
CLARIVATE PLC: -8.96% (2.29$)
Lemonade Inc: -8.47% (71.02$)

AI analysis for FuelCell Energy: https://t.co/PkqWnSaan6
$FCEL JACK CLVT LMND

[Leeway @PWPLeewayEN]

Current #Russell2000 Top #Stocks!

Penguin Solutions, Inc.: 18.25% (74.16$)
Prime Medicine, Inc. Common Stock: 16.17% (4.63$)
Beazer Homes USA Inc: 14.97% (31.52$)
Elicio Therapeutics Inc.: 14.64% (3.21$)

AI analysis for Penguin Solutions: https://t.co/nbBeeDANYb
$PENG PRME BZH ELTX

[zerohedge @zerohedge]

DB on the biggest market paradox:

"Even as futures price in 2026 Fed rate hikes, other assets aren’t pricing in the usual consequences of a hawkish Fed. If the Fed really is about to restart a hiking cycle, then financial conditions are remarkably loose. Equities are around record highs, credit spreads remain tight, and broader risk appetite looks fine. This is quite different to recent occasions the Fed started hiking, including the last couple of times in early 2022, and again in late-2015. Indeed, Bloomberg’s financial conditions index is currently at one of its most accommodative levels in the last decade.

Moreover, it’s very rare for the Fed to just deliver a token move and then reverse course, as market pricing implies. Overwhelmingly in recent decades, the Fed tends to deliver a full-blown hiking cycle once they start hiking, rather than a simple “one and done”.

In both respects, market pricing seems paradoxical. Fed rate hikes are being priced in, but financial conditions remain highly accommodative. And it would be historically unusual if just one hike occurred, given the Fed tend to launch into multiple rate hikes once they start."

[Leeway @PWPLeewayEN]

🏦 𝐔𝐏𝐃𝐀𝐓𝐄 | Powered by Leeway AI
$LLY | 𝐓𝐡𝐞 𝐎𝐫𝐚𝐥 𝐆𝐋𝐏−𝟏 𝐋𝐚𝐧𝐝 𝐆𝐫𝐚𝐛

𝐓𝐋;𝐃𝐑 Lilly launches Foundayo, the first oral GLP-1 pill, while Q1 revenue jumps 𝟓𝟓.𝟓% to $𝟏𝟗.𝟖𝐁. The pipeline (Retatrutide) is now flirting with surgery-level efficacy. This is scale meeting a category shift. The center of gravity here is 𝐅𝐨𝐮𝐧𝐝𝐚𝐲𝐨 (𝐨𝐫𝐟𝐨𝐫𝐠𝐥𝐢𝐩𝐫𝐨𝐧), the first oral GLP-1 small molecule to clear the FDA. That matters less for its opening week and more for what it removes: the injection. ℹ️ The early script count trails Novo's oral Wegovy (1,390 vs 3,071), but roughly 𝟖𝟎% of those patients were new to GLP-1 entirely. Lilly isn't fighting over Novo's existing users yet; it's pulling fresh demand into the category. The commercial lever is pricing.

📅 From July 1, 2026, Medicare Part D beneficiaries get Foundayo at $𝟓𝟎/month, with permanent Medicare reimbursement groundwork laid for 2028. That's the kind of access mechanism that turns a launch curve into a volume curve.

📈 Q1 2026 revenue hit $𝟏𝟗.𝟖𝐁, 𝐮𝐩 𝟓𝟓.𝟓% 𝐲𝐞𝐚𝐫−𝐨𝐯𝐞𝐫−𝐲𝐞𝐚𝐫, and management raised full-year guidance to $𝟖𝟐−𝟖𝟓𝐁. Growth at that revenue base is unusual; companies this size rarely accelerate. The pipeline reads even louder than the print. 𝐑𝐞𝐭𝐚𝐭𝐫𝐮𝐭𝐢𝐝𝐞, the triple-agonist, showed 𝟐𝟖−𝟑𝟎% average weight reduction in Phase 3, with ~𝟒𝟓% of patients losing more than 𝟑𝟎% of body weight. That's territory previously reserved for bariatric surgery, and it reframes what "next-gen" means in this class. ℹ️ 𝐎𝐧𝐞 𝐪𝐮𝐢𝐞𝐭𝐞𝐫 𝐭𝐚𝐢𝐥𝐰𝐢𝐧𝐝:
the FDA is reviewing removal of tirzepatide and semaglutide from compounding pharmacy lists. If that closes, the cheap-copy channel shrinks and both Lilly and Novo capture demand that was leaking out the side door. 𝐊𝐞𝐲 𝐃𝐫𝐢𝐯𝐞𝐫𝐬:

• 𝐅𝐢𝐫𝐬𝐭−𝐌𝐨𝐯𝐞𝐫 𝐢𝐧 𝐎𝐫𝐚𝐥 𝐆𝐋𝐏−𝟏: Foundayo is the first oral GLP-1 small molecule approved. 𝟖𝟎% of early patients are new to the category, expanding the market rather than splitting it.
• 𝐑𝐞𝐯𝐞𝐧𝐮𝐞 𝐀𝐜𝐜𝐞𝐥𝐞𝐫𝐚𝐭𝐢𝐨𝐧: Q1 revenue $𝟏𝟗.𝟖𝐁 (+𝟓𝟓.𝟓% YoY), guidance raised to $𝟖𝟐−𝟖𝟓𝐁. Rare growth acceleration at this scale.
• 𝐏𝐢𝐩𝐞𝐥𝐢𝐧𝐞 𝐎𝐩𝐭𝐢𝐨𝐧𝐚𝐥𝐢𝐭𝐲: Retatrutide's 𝟐𝟖−𝟑𝟎% average weight loss approaches surgical outcomes, positioning Lilly a full generation ahead in efficacy.

🧠 𝐋𝐞𝐞𝐰𝐚𝐲 𝐕𝐞𝐫𝐝𝐢𝐜𝐭:
Watch the Foundayo script trajectory into the July 2026 Medicare access date—that's when volume should decouple from the sluggish opening week. The compounding decision and Retatrutide's regulatory path are the two swing factors that could widen the gap with Novo further. Manufacturing capacity, not demand, is the constraint worth monitoring.

📉 Full Data & Interactive Charts: https://leeway. tech/en/aktienanalyse/Eli%20Lilly%20and%20Company

Disclaimer: This is not financial advice. Based on Leeway AI model outputs.

LLY SPX500 EUSTX50

[Leeway @PWPLeewayEN]

📊 Monthly performance in EUR:

+4.4% #Nikkei
+3.7% #Stoxx50
+0.5% #Nasdaq100
+0.4% #MSCIWorld
+0.4% #SP500
+0.1% #FTSE100
-0.3% #DAX
-7.5% #Nvidia
-8.0% #Gold
-14.9% #SAP
-16.8% #Bitcoin
-18.8% #Ethereum
-20.1% #Silber
-23.6% #Rheinmetall

#Investing #Markets #Stocks

[Leeway @PWPLeewayEN]

Current #Russell2000 Flop #Stocks!

Unicycive Therapeutics Inc: -45.32% (4.21$)
Sable Offshore Corp.: -44.55% (3.87$)
Nuvectis Pharma Inc: -31.51% (19.54$)
Concentrix Corporation: -20.06% (20.17$)

AI analysis for Unicycive Therapeutics: https://t.co/XPbyHaGeEA
$UNCY SOC NVCT CNXC

[LeewayTech @quant1212]

If it is beer you believe in

[Leeway @PWPLeewayEN]

Leeway AI: Beer pure-play faces volume headwinds amid capacity expansion gamble
$STZ

Constellation Brands has streamlined its portfolio dramatically, divesting large portions of its wine and spirits business so that beer now represents roughly 91% of revenue.

The investment thesis has narrowed almost entirely to Mexican-brewed import beer.

The company is committing substantial capital to expand brewing capacity in Mexico—over $700 million in FY2026 alone, with another $800 million planned for FY2027—a commitment that strains the balance sheet and introduces execution risk.The beer business itself faces headwinds.

Depletions declined 5.3% over a 12-week period, and management reports a pronounced demand drop in products disproportionately purchased by Hispanic consumers, driven by intensified immigration enforcement activity and economic stress within that demographic.Compounding operational challenges, the company executed a CEO transition while planning to eliminate over 90% of its internal IT workforce and outsource those functions to Infosys in India, raising operational and cybersecurity concerns.

On the positive side, the company continues to generate strong free cash flow of approximately $1.8 billion in FY2026, has paid down nearly $2 billion in debt since 2022, and maintains consistent capital returns to shareholders.

https://t.co/JcdKawI5aa

[Leeway @PWPLeewayEN]

Leeway AI: Beer pure-play faces volume headwinds amid capacity expansion gamble
$STZ

Constellation Brands has streamlined its portfolio dramatically, divesting large portions of its wine and spirits business so that beer now represents roughly 91% of revenue.

The investment thesis has narrowed almost entirely to Mexican-brewed import beer.

The company is committing substantial capital to expand brewing capacity in Mexico—over $700 million in FY2026 alone, with another $800 million planned for FY2027—a commitment that strains the balance sheet and introduces execution risk.The beer business itself faces headwinds.

Depletions declined 5.3% over a 12-week period, and management reports a pronounced demand drop in products disproportionately purchased by Hispanic consumers, driven by intensified immigration enforcement activity and economic stress within that demographic.Compounding operational challenges, the company executed a CEO transition while planning to eliminate over 90% of its internal IT workforce and outsource those functions to Infosys in India, raising operational and cybersecurity concerns.

On the positive side, the company continues to generate strong free cash flow of approximately $1.8 billion in FY2026, has paid down nearly $2 billion in debt since 2022, and maintains consistent capital returns to shareholders.

https://t.co/JcdKawI5aa

[LeewayTech @quant1212]

@Arkasiraee So its a fancy 3D printer, is what you are saying?

[Leeway @PWPLeewayEN]

📊 Leeway Weekly TL;DR

The Gulf risk returned but the market is pricing it as contained, while hot inflation keeps the Fed boxed and a tech wobble shows again how the sector has become the index.

[LeewayTech @quant1212]

Well, well, the AI flagged it.

The litigation risk into the summer was fairly priced, said the AI when $BAYN was at $46 in February.

In the months after the stock gave beautiful entries and now into the binary resolved again right into that $46 zone.

Our AI deepdive on point.

[Leeway @PWPLeewayEN]

https://t.co/otxguQn37z

[Leeway @PWPLeewayEN]

https://t.co/otxguQn37z

[Leeway @PWPLeewayEN]

🏦 𝐔𝐏𝐃𝐀𝐓𝐄 | Powered by Leeway AI
$BESI. NV | 𝐇𝐲𝐛𝐫𝐢𝐝−𝐁𝐨𝐧𝐝𝐢𝐧𝐠 𝐆𝐨𝐞𝐬 𝐌𝐚𝐢𝐧𝐬𝐭𝐫𝐞𝐚𝐦

𝐓𝐋;𝐃𝐑 Order intake doubled to €𝟐𝟔𝟗.𝟕M, entirely AI-driven. A second HBM customer entering qualification moves hybrid-bonding from niche to standard. BESI lifted long-term revenue targets up to 𝟗𝟎%, while two equipment giants circle.

📈 𝐓𝐡𝐞 𝐜𝐚𝐭𝐚𝐥𝐲𝐬𝐭 𝐢𝐬 𝐨𝐫𝐝𝐞𝐫 𝐢𝐧𝐭𝐚𝐤𝐞. Q1 2026 bookings reached €𝟐𝟔𝟗.𝟕 million, up 𝟏𝟎𝟒.𝟓% year-over-year, and management attributes essentially all of it to AI infrastructure and hybrid-bonding demand. Order growth tends to lead revenue, so this is the number that frames the next several quarters. ℹ️ 𝐓𝐡𝐞 𝐬𝐭𝐫𝐮𝐜𝐭𝐮𝐫𝐚𝐥 𝐬𝐡𝐢𝐟𝐭 𝐬𝐢𝐭𝐬 𝐮𝐧𝐝𝐞𝐫𝐧𝐞𝐚𝐭𝐡 𝐭𝐡𝐞 𝐧𝐮𝐦𝐛𝐞𝐫. A second major customer has begun qualifying HBM hybrid-bonding. One customer is a bet; two is a pattern. That second qualification is what turns a specialized technique into the expected method for high-bandwidth memory and AI servers, which is the difference between a cyclical upswing and a platform transition.

📈 𝐌𝐚𝐧𝐚𝐠𝐞𝐦𝐞𝐧𝐭 𝐩𝐮𝐭 𝐢𝐭𝐬 𝐜𝐨𝐧𝐯𝐢𝐜𝐭𝐢𝐨𝐧 𝐢𝐧 𝐰𝐫𝐢𝐭𝐢𝐧𝐠. At the June 18 investor day, BESI raised long-term targets to €𝟏.𝟕−𝟐.𝟐 billion in revenue and a 𝟒𝟓−𝟓𝟓% operating margin, an increase of up to 𝟗𝟎% over prior guidance. Raising the ceiling by that magnitude is not housekeeping; it signals the company believes the demand curve has reset, not merely flexed.

✅ 𝐓𝐡𝐞 𝐬𝐭𝐫𝐚𝐭𝐞𝐠𝐢𝐜 𝐰𝐞𝐛 𝐢𝐬 𝐭𝐢𝐠𝐡𝐭𝐞𝐧𝐢𝐧𝐠. Applied Materials, holding roughly 𝟗% since April 2025, co-developed the hybrid-bonding platform and extended cooperation by five years. Lam Research has signaled acquisition interest. When two of the largest semiconductor equipment names orbit the same small Dutch specialist, it tells you who they think owns the bottleneck technology.

✅ 𝐁𝐚𝐥𝐚𝐧𝐜𝐞 𝐬𝐡𝐞𝐞𝐭 𝐦𝐨𝐯𝐞𝐬 𝐛𝐚𝐜𝐤 𝐭𝐡𝐞 𝐬𝐭𝐨𝐫𝐲. BESI repurchased €𝟏𝟕𝟓 million in convertible bonds ahead of schedule and launched a further €𝟔𝟎 million buyback. Retiring convertibles early reduces future dilution risk; the buyback says management would rather hold its own equity than pay it out. Both gestures lean the same direction. 𝐊𝐞𝐲 𝐃𝐫𝐢𝐯𝐞𝐫𝐬:

• 𝐎𝐫𝐝𝐞𝐫 𝐈𝐧𝐟𝐥𝐞𝐜𝐭𝐢𝐨𝐧: Q1 2026 intake €𝟐𝟔𝟗.𝟕M, +𝟏𝟎𝟒.𝟓% YoY, AI-driven
• 𝐓𝐞𝐜𝐡𝐧𝐨𝐥𝐨𝐠𝐲 𝐀𝐝𝐨𝐩𝐭𝐢𝐨𝐧: Second customer qualifies HBM hybrid-bonding — niche to standard
• 𝐑𝐚𝐢𝐬𝐞𝐝 𝐓𝐫𝐚𝐣𝐞𝐜𝐭𝐨𝐫𝐲: Long-term targets lifted to €𝟏.𝟕−𝟐.𝟐B revenue, 𝟒𝟓−𝟓𝟓% operating margin (up to +𝟗𝟎%)

🧠 𝐋𝐞𝐞𝐰𝐚𝐲 𝐕𝐞𝐫𝐝𝐢𝐜𝐭:
The thesis hinges on conversion: order intake has doubled, but the second HBM qualification still needs to move from testing to production volume. Watch whether that customer ramps on schedule, and watch the Applied/Lam dynamic — strategic interest at 𝟗% ownership rarely stays static, and a bid would reprice the conversation entirely.

📉 Full Data & Interactive Charts: https://leeway. tech/en/aktienanalyse/BE%20Semiconductor%20Industries

Disclaimer: This is not financial advice. Based on Leeway AI model outputs.

BESI. NV SPX500 EUSTX50

[Leeway @PWPLeewayEN]

📊 Leeway Daily TL;DR

Micron's strong numbers and AI guidance after Wednesday's US close steadied a tech tape that had been bracing for disappointment, lifting futures and sending the Nikkei up over 3%. The relief is real, but it rests on the same handful of names. The Fed gave the big banks a clean stress-test result, oil kept draining, and the dollar firmed to a yearly high against the euro.

[Leeway @PWPLeewayEN]

Current #Russell2000 Top #Stocks!

Nuvectis Pharma Inc: 39.89% (24.55$)
Absci Corp: 35.9% (10.07$)
Domo Inc: 22.77% (2.75$)
Optimum Communications, Inc.: 19.63% (1.61$)

AI analysis for Nuvectis Pharma: https://t.co/BBhbMMbUBa
$NVCT ABSI DOMO OPTU

[Leeway @PWPLeewayEN]

🏦 𝐔𝐏𝐃𝐀𝐓𝐄 | Powered by Leeway AI
$MSFT | 𝐓𝐡𝐞 𝐂𝐨𝐬𝐭 𝐨𝐟 𝐎𝐰𝐧𝐢𝐧𝐠 𝐀𝐈

𝐓𝐋;𝐃𝐑 Microsoft is spending to control its AI stack end-to-end: own chips, own energy, own model diversity. Capex hit $𝟑𝟕.𝟓𝐁 a quarter. The open question isn't capability anymore, it's whether monetization can keep up with the build-out. The strategy here is vertical integration, and Microsoft is paying for it up front. ℹ️ A 𝟐𝟎−𝐲𝐞𝐚𝐫 𝐞𝐧𝐞𝐫𝐠𝐲 𝐬𝐮𝐩𝐩𝐥𝐲 𝐝𝐞𝐚𝐥 𝐰𝐢𝐭𝐡 𝐂𝐡𝐞𝐯𝐫𝐨𝐧 powers the Texas data centers, while the in-house 𝐌𝐚𝐢𝐚 𝟐𝟎𝟎 𝐜𝐡𝐢𝐩 is now in production at roughly 𝟑𝟎% 𝐛𝐞𝐭𝐭𝐞𝐫 𝐩𝐞𝐫𝐟𝐨𝐫𝐦𝐚𝐧𝐜𝐞 𝐩𝐞𝐫 𝐝𝐨𝐥𝐥𝐚𝐫 than external GPUs. The logic is to stop renting the AI stack and start owning it. That ambition has a price tag. ⚠️ Quarterly capex has climbed to $𝟑𝟕.𝟓 𝐛𝐢𝐥𝐥𝐢𝐨𝐧, which is pressing free cash flow and raising the only question that matters right now: can AI revenue scale fast enough to justify the spend. 📈 𝐌𝐢𝐜𝐫𝐨𝐬𝐨𝐟𝐭 𝟑𝟔𝟓 𝐂𝐨𝐩𝐢𝐥𝐨𝐭 at $𝟑𝟎 𝐩𝐞𝐫 𝐮𝐬𝐞𝐫 𝐩𝐞𝐫 𝐦𝐨𝐧𝐭𝐡 across a large installed base is the answer Microsoft is betting on, though implementation costs tend to hide in deployment and can slow adoption velocity more than the per-seat math suggests. ℹ️ 𝐀 𝐪𝐮𝐢𝐞𝐭𝐞𝐫 𝐛𝐮𝐭 𝐦𝐞𝐚𝐧𝐢𝐧𝐠𝐟𝐮𝐥 𝐦𝐨𝐯𝐞:
𝐀𝐧𝐭𝐡𝐫𝐨𝐩𝐢𝐜 𝐛𝐞𝐜𝐨𝐦𝐞𝐬 𝐚 𝐬𝐮𝐛𝐩𝐫𝐨𝐜𝐞𝐬𝐬𝐨𝐫 𝐟𝐨𝐫 𝐌𝟑𝟔𝟓 𝐂𝐨𝐩𝐢𝐥𝐨𝐭 𝐟𝐫𝐨𝐦 𝐉𝐚𝐧𝐮𝐚𝐫𝐲 𝟐𝟎𝟐𝟔, reducing single-vendor dependence on OpenAI. That diversification is strategically sensible, though it opens fresh questions on data control and enterprise governance.

⚠️ The 𝐖𝐢𝐧𝐝𝐨𝐰𝐬 𝐑𝐞𝐜𝐚𝐥𝐥 feature is the blemish. A researcher showed malware can bypass its authentication and reach recorded screen data, and Microsoft declining to classify this as a vulnerability compounds both regulatory and reputational exposure. Small in dollar terms, but the kind of thing enterprise buyers remember when trust is the product. 𝐊𝐞𝐲 𝐃𝐫𝐢𝐯𝐞𝐫𝐬:

• 𝐕𝐞𝐫𝐭𝐢𝐜𝐚𝐥 𝐈𝐧𝐭𝐞𝐠𝐫𝐚𝐭𝐢𝐨𝐧: Maia 200 chip in production at ~𝟑𝟎% better performance per dollar; 20-year Chevron energy deal for Texas data centers.
• 𝐂𝐚𝐩𝐞𝐱 𝐯𝐬. 𝐌𝐨𝐧𝐞𝐭𝐢𝐳𝐚𝐭𝐢𝐨𝐧: $𝟑𝟕.𝟓𝐁 quarterly capex pressuring free cash flow against $𝟑𝟎/user/month Copilot revenue ramp.
• 𝐌𝐨𝐝𝐞𝐥 𝐃𝐢𝐯𝐞𝐫𝐬𝐢𝐟𝐢𝐜𝐚𝐭𝐢𝐨𝐧: Anthropic joins as M365 Copilot subprocessor in Jan 2026, easing OpenAI dependency but adding governance questions.

🧠 𝐋𝐞𝐞𝐰𝐚𝐲 𝐕𝐞𝐫𝐝𝐢𝐜𝐭:
Watch the gap between capex and Copilot revenue over the next two to three quarters. The infrastructure thesis is sound; the timing risk is whether monetization arrives before the spending fatigues investors. The Recall issue is minor financially but worth tracking as a signal of how carefully Microsoft handles enterprise trust.

📉 Full Data & Interactive Charts: https://leeway. tech/en/aktienanalyse/Microsoft

Disclaimer: This is not financial advice. Based on Leeway AI model outputs.

MSFT SPX500 EUSTX50

[Leeway @PWPLeewayEN]

🎯 Stocks Resume Decline as Chipmakers and AI Companies Fall

$AAL ALK AMD

The S&P 500 Index (SPX) (SPY) today is down -0.61%, the Dow Jones Industrial Average (DOWI) (DIA) is down -0.88%, and the Nasdaq 100 Index (IUXX) (QQQ) is down -0.80%.  June E-mini S&P futures (ESM26) are down -0.71%, and June E-mini Nasdaq futures (NQM26) are down -0.97%.

Stock indexes are sliding for a second day today, as chipmakers and AI-infrastructure stocks retreat.  Also, rising crude oil prices are weighing on airline stocks, and ...

Read news: https://t.co/OgsQ8R9QFj